Loading...

Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 64.27 USD +2.6% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

The intrinsic value of one CTLT stock under the Base Case scenario is 80 USD. Compared to the current market price of 64.27 USD, Catalent Inc is Undervalued by 20%.

The Intrinsic Value is calculated as the average of the two valuation methods:

CTLT Intrinsic Value
Base Case
80 USD
Undervaluation 20%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

CTLT Profitability Score
Profitability Due Diligence

Catalent Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Negative Free Cash Flow
Positive 3-Year Average ROIC
Positive ROIC
Positive ROE
51/100
Profitability
Score

Catalent Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

CTLT Solvency Score
Solvency Due Diligence

Catalent Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Average Interest Coverage
Positive Net Debt
Low Altman Z-Score
Low D/E
38/100
Solvency
Score

Catalent Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Catalent Inc

Current Assets 2.9B
Cash & Short-Term Investments 470M
Receivables 1.4B
Other Current Assets 1B
Non-Current Assets 8.2B
PP&E 3.6B
Intangibles 4.3B
Other Non-Current Assets 390M
Current Liabilities 1.5B
Accounts Payable 367M
Accrued Liabilities 318M
Other Current Liabilities 841M
Non-Current Liabilities 4.7B
Long-Term Debt 4.2B
Other Non-Current Liabilities 488M
Efficiency
33%
Gross Margin
14%
Operating Margin
9%
Net Margin
-8%
FCF Margin
Other

CTLT Capital Structure
Catalent Inc

Market Capitalization 11.6B USD
Total Debt 4.2B USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 442M USD
Short-Term Investments 28M USD
Enterprise Value 15.3B USD

Wall St
Price Targets

CTLT Price Targets Summary
Catalent Inc

Wall Street analysts forecast CTLT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTLT is 80.5 USD with a low forecast of 55.55 USD and a high forecast of 94.5 USD.

Lowest
Price Target
55.55 USD
14% Downside
Average
Price Target
80.5 USD
25% Upside
Highest
Price Target
94.5 USD
47% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

CTLT Competitors
Catalent Inc

CTLT Suppliers & Customers
Catalent Inc

Suppliers Map
Customers Map

Ownership

CTLT Insider Trading
Buy and sell transactions by insiders

Catalent Inc insiders have only sold shares in the past 12 months.

During the last 12 months Catalent Inc insiders have not bought any shares, and sold 10.5M USD worth of shares. The last transaction was made on Mar 25, 2023 by Hopson Ricky (Pres. Clinical Dev Supply Div), who sold 31.7k USD worth of CTLT shares.

Sold
0-3
months
31.7k USD
1
3-6
months
274k USD
3
6-9
months
9.7M USD
17
9-12
months
548k USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
31.7k USD
N/A
-31.7k
6 Months
305k USD
N/A
-305.5k
9 Months
10M USD
N/A
-10M
12 Months
10.5M USD
N/A
-10.5M
Purchases
9
Sales
167
No transactions found
Why is insider trading important?

Shareholder Return

CTLT Return Decomposition
Main factors of price return

Market capitalization of CTLT shares increased by 114.23% over the past 5 years. The primary factor behind the change was an increase in earnings growth from 62.7M to 409M, leading to a growth in the market capitalization of Catalent Inc by 281.18%.

Market capitalization of CTLT shares increased by 114.23% over the past 5 years. The primary factor behind the change was an increase in earnings growth from 62.7M to 409M, leading to a growth in the market capitalization of Catalent Inc by 281.18%.

+114.23%
5.4B 11.6B
Market Cap Growth
-166.94%
86.1 28.3
P/E Change
+281.18%
62.7M 409M
Earnings Growth
Market Cap Growth
+114.23%
P/E Change
-166.94%
Earnings Growth
+281.18%
What is price return decomposition?

CTLT Price
Catalent Inc

1M 1M
-4%
6M 6M
-14%
1Y 1Y
-40%
3Y 3Y
+33%
5Y 5Y
+59%
Annual Price Range
64.27
52w Low
41.39
52w High
114.05
Price Metrics
Average Annual Return 40.67%
Standard Deviation of Annual Returns 52.24%
Max Drawdown -71%
Shares Statistics
Market Capitalization 11.6B USD
Shares Outstanding 181 000 000
Percentage of Shares Shorted 2.23%

Company Profile

Catalent Inc Logo
Catalent Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

11.6B USD

Dividend Yield

0%

Description

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

Contact

NEW JERSEY
Somerset
14 Schoolhouse Rd
+17325376200.0
https://www.catalent.com/

IPO

2014-07-31

Employees

17 300

Officers

Exec. Chair of the Board
Mr. John R. Chiminski
CEO & Director
Mr. Alessandro Maselli
Sr. VP & CFO
Mr. Thomas P. Castellano
Exec. VP, Corp. Sec. & Chief Admin. Officer
Mr. Steven L. Fasman Esq.
Group Pres of Pharma & Consumer Health Segment
Dr. Aristippos Gennadios Ph.D.
Pres & Division Head for Clinical Devel. and Supply
Mr. Ricky Hopson
Show More
VP & Chief Accounting Office
Ms. Karen Murphy Santiago
VP & Chief Scientific Officer
Mr. Julien Meissonnier
Sr. VP & Chief Information Officer
Mr. Charles Lickfold
VP of Investor Relations
Mr. Paul Surdez
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one CTLT stock?

The intrinsic value of one CTLT stock under the Base Case scenario is 80 USD.

Is CTLT stock undervalued or overvalued?

Compared to the current market price of 64.27 USD, Catalent Inc is Undervalued by 20%.